Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TMB 380

Next Previous
Drug Profile

TMB 380

Alternative Names: TMB-380; VRC-HIVMAB075-00-AB; VRC07 523LS

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases; TaiMed Biologics; University of California at San Francisco
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action HIV envelope protein gp120 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 23 May 2025 National Institute of Allergy and Infectious Diseases plans a phase I trial for HIV-1 infection (Treatment experienced, Combination therapy) in the US, Brazil and Peru (IV, Infusion) in June 2025 (NCT06987318)
  • 17 Mar 2025 TMB 380 is available for licensing as of 17 Mar 2025. https://www.taimedbiologics.com/index.php?lang=en
  • 17 Mar 2025 Efficacy and adverse events data from a phase Ib/IIa trial in HIV-1 infections released by TaiMed Biologics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top